← Leaderboards

Catherine Mary Bollard

Children'S Research Institute

Google Scholar ↗PubMed ↗ORCID ↗

$14,999,215

Attributed

$22,427,371

Total exposure

39

Grants

32

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5.9M · FY2005–25

$10M$7.5M$5M$2.5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$46,871,384 · 40

By mechanism

P01$29,272,803 · 5

OT2$3,968,330 · 1

R01$3,776,636 · 1

U01$3,221,135 · 1

R33$2,561,133 · 1

UG1$1,835,749 · 1

Top collaborators

Others in their field

Top investigators on “T-Lymphocyte”

Barton F Haynes · Duke University$296,833,570
Lawrence Corey · Fred Hutchinson Cancer Center$270,341,865
Dan H. Barouch · Fred Hutchinson Cancer Center$117,305,894
Margaret Juliana McElrath · Fred Hutchinson Cancer Center$107,651,960
Alessandro Sette · La Jolla Institute For Immunology$75,756,097
Rama Rao Amara · Emory University$69,530,112

Research focus

T-LymphocyteCellsClinical TrialsTransplantationInfusion ProceduresAntigensImmuneImmunityResearch PersonnelVirusCytotoxic T-LymphocytesViralAllogenicMalignant NeoplasmsRelapseAdoptive TransferTumorIn VivoInfectionIncidenceSourceResponseHuman Herpesvirus 4Child

Grant awards (94)

NextGen - CRI$1,440,060

OT2 · FY2025 · CA · contact PI

BMT CTN Core: Baylor College of Medicine Consortium$230,545

UG1 · FY2025 · HL

Children's Research Institute Hematology Research Training Grant$149,367

T32 · FY2025 · HL

NextGen - CRI$918,661

OT2 · FY2024 · CA · contact PI

BMT CTN Core: Baylor College of Medicine Consortium$242,183

UG1 · FY2024 · HL

Children's Research Institute Hematology Research Training Grant$113,919

T32 · FY2024 · HL

Antigen Specific T Cells$19,524

P01 · FY2024 · CA · contact PI

NextGen - CRI$738,441

OT2 · FY2023 · CA · contact PI

Antigen Specific T Cells$205,353

P01 · FY2023 · CA · contact PI

Targeting HIV and EBV Antigens in Patients with HIV Lymphoma$195,745

UG1 · FY2023 · HL

Novel Cord Blood-Derived Cellular Therapies$2,549,929

P01 · FY2022 · CA

NextGen - CRI$871,168

OT2 · FY2022 · CA · contact PI

Enhancing cell therapy for brain tumors$636,818

U01 · FY2022 · CA · contact PI

Multivirus-specific T Cells from Naive CB-derived T Cells$491,294

P01 · FY2022 · CA · contact PI

Antigen Specific T Cells$205,353

P01 · FY2022 · CA · contact PI

Targeting HIV and EBV Antigens in Patients with HIV Lymphoma$195,745

UG1 · FY2022 · HL

Rationale for the Pediatric Hematology and Transfusion Medicine Multidisciplinary Research Training Award (PHTMMRT) at Children?s National$123,868

T32 · FY2022 · HL

Cancer Immunotherapy Winter School (CIWS)$30,000

R13 · FY2022 · CA · contact PI

Novel Cord Blood-Derived Cellular Therapies$2,569,848

P01 · FY2021 · CA

Mesenchymal Stromal Cell Delivery through Cardiopulmonary Bypass in Pediatric Cardiac Surgery$813,164

R33 · FY2021 · HL

Enhancing cell therapy for brain tumors$636,455

U01 · FY2021 · CA · contact PI

Multivirus-specific T Cells from Naive CB-derived T Cells$501,150

P01 · FY2021 · CA · contact PI

Rationale for the Pediatric Hematology and Transfusion Medicine Multidisciplinary Research Training Award (PHTMMRT) at Children?s National$221,091

T32 · FY2021 · HL

Antigen Specific T Cells$205,353

P01 · FY2021 · CA · contact PI

Targeting HIV and EBV Antigens in Patients with HIV Lymphoma$195,745

UG1 · FY2021 · HL

Novel Cord Blood-Derived Cellular Therapies$2,576,646

P01 · FY2020 · CA

Mesenchymal Stromal Cell Delivery through Cardiopulmonary Bypass in Pediatric Cardiac Surgery$866,762

R33 · FY2020 · HL

HIV-specific ex-vivo expanded T cell therapy (HXTC) to Deplete the Latent Reservoir of Persistent HIV Infection$735,324

R01 · FY2020 · HL

Enhancing cell therapy for brain tumors$636,807

U01 · FY2020 · CA · contact PI

Multivirus-specific T Cells from Naive CB-derived T Cells$505,999

P01 · FY2020 · CA · contact PI

Antigen Specific T Cells$205,353

P01 · FY2020 · CA · contact PI

Targeting HIV and EBV Antigens in Patients with HIV Lymphoma$195,745

UG1 · FY2020 · HL

Rationale for the Pediatric Hematology and Transfusion Medicine Multidisciplinary Research Training Award (PHTMMRT) at Children?s National$185,306

T32 · FY2020 · HL

Novel Cord Blood-Derived Cellular Therapies$2,508,224

P01 · FY2019 · CA

Mesenchymal Stromal Cell Delivery through Cardiopulmonary Bypass in Pediatric Cardiac Surgery$881,207

R33 · FY2019 · HL

HIV-specific ex-vivo expanded T cell therapy (HXTC) to Deplete the Latent Reservoir of Persistent HIV Infection$735,324

R01 · FY2019 · HL

Enhancing cell therapy for brain tumors$636,799

U01 · FY2019 · CA · contact PI

Multivirus-specific T Cells from Naive CB-derived T Cells$494,170

P01 · FY2019 · CA · contact PI

Antigen Specific T Cells$221,290

P01 · FY2019 · CA · contact PI

Targeting HIV and EBV Antigens in Patients with HIV Lymphoma$195,745

UG1 · FY2019 · HL

Rationale for the Pediatric Hematology and Transfusion Medicine Multidisciplinary Research Training Award (PHTMMRT) at Children?s National$67,885

T32 · FY2019 · HL

Novel Cord Blood-Derived Cellular Therapies$1,966,908

P01 · FY2018 · CA

HIV-specific ex-vivo expanded T cell therapy (HXTC) to Deplete the Latent Reservoir of Persistent HIV Infection$735,214

R01 · FY2018 · HL

Enhancing cell therapy for brain tumors$674,256

U01 · FY2018 · CA · contact PI

Multivirus-specific T Cells from Naive CB-derived T Cells$520,650

P01 · FY2018 · CA · contact PI

Targeting HIV and EBV Antigens in Patients with HIV Lymphoma$185,957

UG1 · FY2018 · HL

Rationale for the Pediatric Hematology and Transfusion Medicine Multidisciplinary Research Training Award (PHTMMRT) at Children?s National$81,165

T32 · FY2018 · HL

HIV-specific ex-vivo expanded T cell therapy (HXTC) to Deplete the Latent Reservoir of Persistent HIV Infection$770,866

R01 · FY2017 · HL

Targeting HIV and EBV Antigens in Patients with HIV Lymphoma$198,339

UG1 · FY2017 · HL

IMPROVING CORD BLOOD TRANSPLANTATION$1,247,007

P01 · FY2016 · CA

HIV-specific ex-vivo expanded T cell therapy (HXTC) to Deplete the Latent Reservoir of Persistent HIV Infection$799,908

R01 · FY2016 · HL

Multivirus-specific T Cells from Naive CB-derived T Cells$85,456

P01 · FY2016 · CA · contact PI

IMPROVING CORD BLOOD TRANSPLANTATION$2,630,723

P01 · FY2015 · CA

Multivirus-specific T Cells from Naive CB-derived T Cells$320,322

P01 · FY2015 · CA · contact PI

IMPROVING CORD BLOOD TRANSPLANTATION$1,030,855

P01 · FY2014 · CA

Multivirus-specific T Cells from Naive CB-derived T Cells$124,306

P01 · FY2014 · CA · contact PI

IMPROVING CORD BLOOD TRANSPLANTATION$2,369,877

P01 · FY2013 · CA

Multivirus-specific T Cells from Naive CB-derived T Cells$423,119

P01 · FY2013 · CA · contact PI

IMPROVING CORD BLOOD TRANSPLANTATION$2,492,597

P01 · FY2012 · CA

Enhancing Treg Immune Reconstitution After Stem Cell Transplant$311,709

R21 · FY2012 · CA · contact PI

Multivirus-specific T Cells from Naive CB-derived T Cells$300,098

P01 · FY2012 · CA · contact PI

Anti-viral and antileukemic T-cell therapy as prophylaxis after HSCT$160,218

U10 · FY2012 · HL · contact PI

IMPROVING CORD BLOOD TRANSPLANTATION$2,501,399

P01 · FY2011 · CA

Enhancing Treg Immune Reconstitution After Stem Cell Transplant$325,834

R21 · FY2011 · CA · contact PI

Anti-viral and antileukemic T-cell therapy as prophylaxis after HSCT$153,253

U10 · FY2011 · HL · contact PI

CLINICAL TRIAL: NEOMYCIN RESISTANCE LMP2A SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR$41,950

M01 · FY2011 · RR · contact PI

ADMINISTRATION OF TGF-B RESISTANT LMP2A-SPECIFIC CYTOTOXIC T-LYMPHOCYTES TO P$14,643

M01 · FY2011 · RR · contact PI

ADOPTIVE TRANSFER OF CORD BLOOD T CELLS TO PREVENT AND TREAT CMV AND ADENOVIRUS$5,936

M01 · FY2011 · RR · contact PI

CLINICAL TRIAL: VIRUS SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR THE PROPHYLAXIS OF CM$5,936

M01 · FY2011 · RR · contact PI

CLINICAL TRIAL: THE ADMINISTRATION OF NEOMYCIN RESISTANCE GENE MARKED EBV SPECI$395

M01 · FY2011 · RR · contact PI

CLINICAL TRIAL: NEOMYCIN RESISTANCE LMP2A SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR E$33,954

M01 · FY2010 · RR · contact PI

CLINICAL TRIAL: VIRUS SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR THE PROPHYLAXIS OF CM$18,312

M01 · FY2010 · RR · contact PI

ADMINISTRATION OF TGF-B RESISTANT LMP2A-SPECIFIC CYTOTOXIC T-LYMPHOCYTES TO P$4,197

M01 · FY2010 · RR · contact PI

CLINICAL TRIAL: ADMINISTRATION OF VIRUS-SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR THE$1,526

M01 · FY2010 · RR · contact PI

CLINICAL TRIAL: NEOMYCIN RESISTANCE LMP2A SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR E$26,959

M01 · FY2009 · RR · contact PI

CLINICAL TRIAL: VIRUS SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR THE PROPHYLAXIS OF CM$13,924

M01 · FY2009 · RR · contact PI

CLINICAL TRIAL: ADMINISTRATION OF VIRUS-SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR THE$1,482

M01 · FY2009 · RR · contact PI

CLINICAL TRIAL: ADMINISTRATION OF NEOMYCIN RESISTANCE GENE MARKED EBV SPECIFIC C$296

M01 · FY2009 · RR · contact PI

CLINICAL TRIAL: NEOMYCIN RESISTANCE LMP2A SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR E$13,162

M01 · FY2008 · RR · contact PI

CLINICAL TRIAL: ADMINISTRATION OF VIRUS-SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR THE$12,269

M01 · FY2008 · RR · contact PI

CLINICAL TRIAL: VIRUS SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR THE PROPHYLAXIS OF CM$5,354

M01 · FY2008 · RR · contact PI

CLINICAL TRIAL: ADMINISTRATION OF NEOMYCIN RESISTANCE GENE MARKED EBV SPECIFIC C$3,569

M01 · FY2008 · RR · contact PI

CLINICAL TRIAL: ADMINISTRATION OF LMP2A-SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOLLOW$223

M01 · FY2008 · RR · contact PI

ADMINISTRATION OF VIRUS-SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR THE PROPHYLAXIS$13,180

M01 · FY2007 · RR · contact PI

VIRUS SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR THE PROPHYLAXIS OF CMV$12,594

M01 · FY2007 · RR · contact PI

NEOMYCIN RESISTANCE LMP2A SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR EBV POS LYMPHOMA$11,716

M01 · FY2007 · RR · contact PI

ADMINISTRATION OF LMP2A-SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOLLOWING CD45 ANTI$879

M01 · FY2007 · RR · contact PI

VIRUS SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR THE PROPHYLAXIS OF CMV$17,990

M01 · FY2006 · RR · contact PI

NEOMYCIN RESISTANCE LMP2A SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR EBV POS LYMPHOMA$14,578

M01 · FY2006 · RR · contact PI

ADMINISTRATION OF LMP2A-SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOLLOWING CD45 ANTI$7,754

M01 · FY2006 · RR · contact PI

NEOMYCIN RESISTANCE LMP2A SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR EBV POS LYMPHOMA$22,900

M01 · FY2005 · RR

ADMINISTRATION OF LMP2A-SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOLLOWING CD45$2,585

M01 · FY2005 · RR

VIRUS SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR THE PROPHYLAXIS OF CMV$739

M01 · FY2005 · RR

Neomycin Resistance LMP2A Specific Cytotoxic T-Lymphocytes for EBV Pos. Lymphoma$2,981

M01 · FY2004 · RR